Geovax Labs Inc
Research Geovax Labs Inc (GOVX) on Bullrun: market cap USD 4.73M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGOVX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.73M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 4.43M
- Free cash flow-USD 3.66M
Valuation Snapshot
latest market cap is USD 4.73M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.49M | -USD 21.46M | -USD 21.50M | n/a | -50.15 | USD 3.09M | USD 843.17K | USD 3.83M |
| FY2024 | USD 3.95M | -USD 24.99M | -USD 24.70M | n/a | -32.03 | USD 5.51M | USD 0 | USD 5.05M |
| FY2023 | USD 0 | -USD 25.97M | -USD 25.22M | n/a | -25.13 | USD 6.45M | n/a | USD 5.76M |
| FY2022 | USD 81.53K | -USD 14.02M | -USD 19.16M | n/a | n/a | USD 27.61M | n/a | USD 26.60M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.73M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.41M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 26.03M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 9.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 16.58M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 23.08M | n/a | n/a | n/a |
About Geovax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Geovax Labs Inc's market cap?
Geovax Labs Inc's market capitalization is USD 4.73M.
What does Geovax Labs Inc do?
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.